Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29189002 | 0.96 | CASP2 (0.55) | CASP2TSHRNAAASMN1; SMN2 | |
| SCHEMBL25801633 | 0.91 | CASP2 (0.52) | CASP2TSHRNAAAFAAH | |
| SCHEMBL22174072 | 0.90 | TSHR (0.52) | CASP2TSHRNAAAFAAH | |
| SCHEMBL18164189 | 0.89 | TSHR (0.55) | CASP2TSHRNAAAFAAH | |
| SCHEMBL5664870 | 0.88 | FAAH (0.60) | CASP2NAAAFAAH | |
| SCHEMBL29105414 | 0.88 | FAAH (0.60) | CASP2NAAAFAAH | |
| SCHEMBL31074228 | 0.88 | FAAH (0.60) | CASP2NAAAFAAH | |
| SCHEMBL30763456 | 0.88 | FAAH (0.60) | CASP2NAAAFAAH | |
| SCHEMBL27805033 | 0.87 | CASP2 (0.52) | CASP2TSHRNAAAFAAH | |
| SCHEMBL19092416 | 0.87 | CASP2 (0.49) | CASP2TSHRNAAAFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221942-A | Heteroatom modified silicon resin and preparation method of high-temperature-resistant adhesive thereof | 哈尔滨工业大学 | 2024-06-21 | — | — | CN | disclosed |
| US-11696959-B2 | Nanoparticle-cell construct with platinum anti-cancer agent | CITY OF HOPE (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2018144954-A1 | SILICA NANOPARTICLE WITH AN INSOLUBLE DRUG | CITY OF HOPE (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2017117275-A1 | SILICA NANOPARTICLE WITH PLATINUM ANTI-CANCER AGENT | CITY OF HOPE (US) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696959-B2 | Nanoparticle-cell construct with platinum anti-cancer agent | CD47, TP53, CD63 | CASP2 783/4885TSHR 4222/4885NAAA 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.